Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    NCT02155647
Previous Study | Return to List | Next Study

Avelumab in Participants With Merkel Cell Carcinoma (JAVELIN Merkel 200)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02155647
Recruitment Status : Active, not recruiting
First Posted : June 4, 2014
Results First Posted : July 22, 2020
Last Update Posted : January 5, 2021
Sponsor:
Information provided by (Responsible Party):
EMD Serono ( EMD Serono Research & Development Institute, Inc. )

Brief Summary:
This is a multicenter, international, single-arm, open-label, Phase 2 trial to evaluate the efficacy and safety of avelumab in participants with metastatic Merkel cell carcinoma (MCC).

Condition or disease Intervention/treatment Phase
Carcinoma, Merkel Cell Drug: Avelumab Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 204 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase II, Open-Label, Multicenter Trial to Investigate the Clinical Activity and Safety of Avelumab (MSB0010718C) in Subjects With Merkel Cell Carcinoma
Actual Study Start Date : July 3, 2014
Actual Primary Completion Date : May 2, 2019
Estimated Study Completion Date : May 3, 2024


Arm Intervention/treatment
Experimental: Part A: Avelumab
Participants with metastatic Merkel cell carcinoma (MCC) after failing first-line chemotherapy received Avelumab at a dose of 10 milligram per kilogram (mg/kg) as 1-hour intravenous infusion once every 2 weeks until therapeutic failure, significant clinical deterioration, unacceptable toxicity, or any criterion for withdrawal from the trial or investigational medicinal product occurs.
Drug: Avelumab
Avelumab was administered at a dose of 10 milligram per kilogram (mg/kg) as 1-hour intravenous infusion once every 2 weeks until therapeutic failure, significant clinical deterioration, unacceptable toxicity, or any criterion for withdrawal from the trial or investigational medicinal product occurs.
Other Names:
  • anti-PD-L1
  • MSB0010718C

Experimental: Part B: Avelumab
Participants received Avelumab as first-line treatment for metastatic or distally recurrent MCC at a dose of 10 mg/kg as 1-hour intravenous infusion once every 2 weeks until therapeutic failure, significant clinical deterioration, unacceptable toxicity, or any criterion for withdrawal from the trial or investigational medicinal product occurs.
Drug: Avelumab
Avelumab was administered at a dose of 10 milligram per kilogram (mg/kg) as 1-hour intravenous infusion once every 2 weeks until therapeutic failure, significant clinical deterioration, unacceptable toxicity, or any criterion for withdrawal from the trial or investigational medicinal product occurs.
Other Names:
  • anti-PD-L1
  • MSB0010718C




Primary Outcome Measures :
  1. Part A: Number of Participants With Confirmed Best Overall Response (BOR) as Per Response Evaluation Criteria in Solid Tumors Version (RECIST) 1.1 [ Time Frame: Up to 87 weeks ]
    Confirmed BOR was determined according to RECIST 1.1and as adjudicated by an Independent Endpoint Review Committee(IERC) and defined as best response of any of complete response (CR), partial response(PR), stable disease(SD) and progressive disease(PD) recorded from date of randomization until disease progression/recurrence(taking smallest measurement recorded since start of treatment as reference). CR:Disappearance of all evidence of target/non-target lesions. PR:At least 30%reduction from baseline in sum of longest diameter(SLD) of all lesions. SD:Neither sufficient increase to qualify for PD nor sufficient shrinkage to qualify for PR. PD:at least a20% increase in SLD, taking as reference smallest SLD recorded from baseline/appearance of 1or more new lesions and unequivocal progression of non-target lesions. CR or PR must be confirmed by a subsequent tumor assessment preferably at next scheduled 6-weekly assessment, but no sooner than 5 weeks after initial documentation of CR or PR.

  2. Part B: Durable Response Rate (DRR) [ Time Frame: Up to 161 weeks ]
    Durable response is defined as an objective response (confirmed complete response [CR] or confirmed Partial response [PR]) according to Response Evaluation Criteria in Solid Tumors version (RECIST) 1.1, determined by the Independent Endpoint Review Committee (IERC), with a duration of at least 6 months. The DRR was determined as the percentage of participants with an objective response in terms of CR or PR according to RECIST 1.1, as determined by the IERC, with a duration of at least 6 months. CR: Disappearance of all evidence of target and non-target lesions. PR: At least 30% reduction from baseline in the sum of the longest diameter (SLD) of all lesions.


Secondary Outcome Measures :
  1. Part A: Duration of Response According to Response Evaluation Criteria in Solid Tumors Version (RECIST) 1.1 [ Time Frame: Up to 87 weeks ]
    The duration of response as determined from IERC tumor assessment was calculated for each participant with a confirmed response (CR or PR) as the time from first observation of response until first observation of documented disease progression or death when death occurs within 12 weeks of the last tumor assessment, whichever occurs first. CR: Disappearance of all evidence of target and non-target lesions. PR: At least 30% reduction from baseline in the sum of the longest diameter (SLD) of all lesions. Results were calculated based on Kaplan-Meier estimates.

  2. Part A: Progression-Free Survival (PFS) Time According to Response Evaluation Criteria in Solid Tumors Version (RECIST) 1.1 [ Time Frame: Up to 87 weeks ]
    The PFS time (based on IERC tumor assessments), according to the RECIST 1.1, was defined as the time from first administration of study treatment until first observation of PD or death when death occurred within 12 weeks of the last tumor assessment or first administration of study treatment (whichever was later). PFS time (in months) was defined as: (date of PD or death - date of the first dose of study treatment + 1)/30.4375 (months). PD was defined as at least a 20% increase in the SLD, taking as reference the smallest SLD recorded from baseline or the appearance of 1 or more new lesions and unequivocal progression of non-target lesions.

  3. Part A: Number of Participants With Treatment-Related (TR) Treatment-Emergent Adverse Events (TEAEs), Treatment-Related Serious TEAEs and Treatment-Related TEAEs Leading to Death [ Time Frame: Up to 87 weeks ]
    Related Adverse events (AE) were defined according to National Cancer Institute Common Terminology Criteria for Adverse Events Version 4.0 (NCI-CTCAE) as adverse events with relationship to study treatment reported by the investigator. A serious adverse event (SAE) was an AE that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial or prolonged inpatient hospitalization; congenital anomaly/birth defect or was otherwise considered medically important. Treatment-emergent are events between first dose of study drug that were absent before treatment or that worsened relative to pre-treatment state up to 30 days after last administration. TEAEs included both Serious TEAEs and non-serious TEAEs. Related TEAEs are defined as events with a relationship of missing, unknown, or yes.

  4. Part A: Number of Participants With Clinically Significant Abnormalities in Laboratory Values Reported as Treatment Emergent Adverse Events (TEAEs) [ Time Frame: Up to 87 weeks ]
    The laboratory measurements included hematology, liver function and blood chemistry. Number of participants with clinically significant abnormalities with Grade greater than or equals to (>=) 3 in laboratory values reported as TEAEs were reported. Clinically Significance was decided by investigator.

  5. Part A: Number of Participants With Clinically Significant Abnormalities in Vital Signs Reported as Treatment Emergent Adverse Events (TEAEs) [ Time Frame: Up to 87 weeks ]
    Vital signs including body temperature, body weight, respiratory rate, heart rate (after 5-minute rest), and arterial blood pressure (after 5-minute rest) were evaluated. Number of participants with clinically significant abnormalities in Vital Signs reported as TEAEs. Clinically Significance was decided by investigator.

  6. Part A: Number of Participants With Clinically Significant Abnormalities in Electrocardiogram (ECG) [ Time Frame: Up to 87 weeks ]
    A 12-lead ECG was recorded after the participant has been in a supine position breathing quietly for 5 minutes. The ECG results was used to evaluate the heart rate, atrial ventricular conduction, PR interval, QRS, QTcF and QTcB. Number of participants with clinical significant abnormalities in ECG parameter reported here. Clinically Significance was decided by investigator.

  7. Part A: Interim Analysis: Overall Survival (OS) Time [ Time Frame: Up to 87 weeks (Data reported are per pre-specified interim analysis with a data cut-off date of 3 Mar 2016) ]
    The OS time was defined as the time from first administration of trial treatment until death. The OS time was analyzed using the Kaplan-Meier method.

  8. Part A: Final Analysis: Overall Survival (OS) Time [ Time Frame: Pre-specified final analysis: Time from first administration of trial treatment until death (Up to 513 weeks) ]
    The OS time was defined as the time from first administration of trial treatment until death. The OS time was analyzed using the Kaplan-Meier method.

  9. Part A: Participant's Response Status According to Response Evaluation Criteria in Solid Tumors Version (RECIST) 1.1 at 6 and 12 Months [ Time Frame: At Month 6 and 12 ]
    The response status at 6 and 12 months after start of trial treatment according to RECIST 1.1 (as determined by the IERC) was determined. A participant was considered to be in response at the given timepoint (6 or 12 months after the start of the participant's treatment) if the participant had a documented response (PR or CR) prior to that timepoint, and neither died nor experienced disease progression according to the RECIST 1.1 nor was lost to follow-up up to the given timepoint. CR: Disappearance of all evidence of target and non-target lesions. PR: At least 30% reduction from baseline in the sum of the longest diameter (SLD) of all lesions. Percentage of participants in response and not in response according to RECIST1.1 at 6 and 12 months were reported.

  10. Part A: Number of Participants With Positive Treatment Emergent Anti-Avelumab Antibodies [ Time Frame: Up to 80 weeks ]
    Serum samples were analyzed by a validated electrochemiluminesce immunoassay to detect the presence of anti-avelumab antibodies. Samples that screened positive were subsequently tested in a confirmatory assay. Those confirmed positive were titered for a quasi-quantitative result. Number of participants with positive treatment emergent anti-Avelumab antibodies were reported. Participants not positive prior to treatment with avelumab and with at least one positive result in the human-Antihuman Antibodies assay were characterized as treatment-emergent.

  11. Part A: Serum Concentration at End of Infusion (CEOI) of Avelumab [ Time Frame: Day 1, 43, 85, 169, 253, 337 and 421 ]
    Serum concentration at end of infusion (CEOI) of Avelumab is reported.

  12. Part A: Minimum Serum Post-dose (Ctrough) Concentration of Aveluamb [ Time Frame: Day 15, 29, 43, 57, 71, 85, 99, 169, 211, 253, 337 and 421 ]
    Minimum serum post-dose (Ctrough) concentration of avelumab was reported.

  13. Part B: Interim Analysis: Overall Survival (OS) Time [ Time Frame: Up to 161 weeks (Data reported are per pre-specified interim analysis with a data cut-off date of 2 May 2019) ]
    The OS time was defined as the time from first administration of study treatment until the date of death. OS was calculated using following formula = (date of death - date of the first dose of study treatment + 1)/30.4375 (months).

  14. Part B: Final Analysis: Overall Survival (OS) Time [ Time Frame: Pre-specified final analysis: Time from first administration of trial treatment until death (Up to 422 weeks) ]
    The OS time was defined as the time from first administration of study treatment until the date of death. OS was calculated using following formula = (date of death - date of the first dose of study treatment + 1)/30.4375 (months).

  15. Part B: Number of Participants With Confirmed Best Overall Response (BOR) as Per Response Evaluation Criteria in Solid Tumors Version (RECIST) 1.1 [ Time Frame: Up to 161 weeks ]
    Confirmed BOR was determined according to RECIST 1.1and as adjudicated by an Independent Endpoint Review Committee(IERC) and defined as best response of any of complete response (CR), partial response(PR), stable disease(SD) and progressive disease(PD) recorded from date of randomization until disease progression/recurrence(taking smallest measurement recorded since start of treatment as reference). CR:Disappearance of all evidence of target/non-target lesions. PR:At least 30%reduction from baseline in sum of longest diameter(SLD) of all lesions. SD:Neither sufficient increase to qualify for PD nor sufficient shrinkage to qualify for PR. PD:at least a20% increase in SLD, taking as reference smallest SLD recorded from baseline/appearance of 1or more new lesions and unequivocal progression of non-target lesions. CR or PR must be confirmed by a subsequent tumor assessment preferably at next scheduled 6-weekly assessment, but no sooner than 5 weeks after initial documentation of CR or PR.

  16. Part B: Duration of Response According to Response Evaluation Criteria in Solid Tumors Version (RECIST) 1.1 [ Time Frame: Up to 161 weeks ]
    The duration of response as determined from IERC tumor assessment was calculated for each participant with a confirmed response (CR or PR) as the time from first observation of response until first observation of documented disease progression or death when death occurs within 12 weeks of the last tumor assessment, whichever occurs first. CR: Disappearance of all evidence of target and non-target lesions. PR: At least 30% reduction from baseline in the sum of the longest diameter (SLD) of all lesions.

  17. Part B: Progression-Free Survival (PFS) Time According to Response Evaluation Criteria in Solid Tumors Version (RECIST) 1.1 [ Time Frame: Up to 161 weeks ]
    The PFS time (based on IERC tumor assessments), according to the RECIST 1.1, was defined as the time from first administration of study treatment until first observation of PD or death when death occurred within 12 weeks of the last tumor assessment or first administration of study treatment (whichever was later). PFS time (in months) was defined as: (date of PD or death - date of the first dose of study treatment + 1)/30.4375 (months). PD was defined as at least a 20% increase in the SLD, taking as reference the smallest SLD recorded from baseline or the appearance of 1 or more new lesions and unequivocal progression of non-target lesions.

  18. Part B: Number of Participants With Treatment-Related (TR) Treatment-Emergent Adverse Events (TEAEs), Treatment-Related Serious TEAEs and Treatment-Related TEAEs Leading to Death [ Time Frame: Up to 161 weeks ]
    Related Adverse events (AE) were defined according to National Cancer Institute Common Terminology Criteria for Adverse Events Version 4.0 (NCI-CTCAE) as adverse events with relationship to study treatment reported by the investigator. A serious adverse event (SAE) was an AE that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial or prolonged inpatient hospitalization; congenital anomaly/birth defect or was otherwise considered medically important. Treatment-emergent are events between first dose of study drug that were absent before treatment or that worsened relative to pre-treatment state up to 30 days after last administration. TEAEs included both Serious TEAEs and non-serious TEAEs. Related TEAEs are defined as events with a relationship of missing, unknown, or yes.

  19. Part B: Participant's Response Status According to RECIST 1.1 at 6 and 12 Months [ Time Frame: At Month 6 and 12 ]
    The response status at 6 and 12 months after start of trial treatment according to RECIST 1.1 (as determined by the IERC) was determined. A participant was considered to be in response at the given timepoint (6 or 12 months after the start of the participant's treatment) if the participant had a documented response (PR or CR) prior to that timepoint, and neither died nor experienced disease progression according to the RECIST 1.1 nor was lost to follow-up up to the given timepoint. CR: Disappearance of all evidence of target and non-target lesions. PR: At least 30% reduction from baseline in the sum of the longest diameter (SLD) of all lesions. Percentage of participants in response and not in response according to RECIST1.1 at 6 and 12 months were reported.

  20. Part B: Number of Participants With Positive Treatment Emergent Anti-Avelumab Antibodies [ Time Frame: Up to 161 weeks ]
    Serum samples were analyzed by a validated electrochemiluminescence immunoassay to detect the presence of antidrug antibodies (ADA). Samples that screened positive were subsequently tested in a confirmatory assay. Those that confirmed positive were titered for a quasi-quantitative result. Number of participants with positive treatment emergent anti-Avelumab antibodies were reported. Participants not positive prior to treatment with avelumab and with at least one positive result in the human-Antihuman Antibodies assay were characterized as treatment-emergent.

  21. Part B: Serum Concentration at End of Infusion (CEOI) of Avelumab [ Time Frame: At Day 1, 43 and 169 ]
    Serum concentration at end of infusion (CEOI) of Avelumab is reported.

  22. Part B: Minimum Serum Post-dose (Ctrough) Concentration of Aveluamb [ Time Frame: Day 15, Day 29, Day 43, Day 85, Day 127, Day 169, Day 253, Day 337, Day 421, Day 505, Day 589, Day 673 ]
    Minimum serum post-dose (Ctrough) concentration of avelumab was reported.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Signed written informed consent
  • Age 18 years and above
  • Histologically proven MCC
  • Participants must have received at least 1 line of chemotherapy for metastatic MCC and must have progressed after the most recent line of chemotherapy
  • For Part B - Participants must not have received any prior systemic treatment for metastatic MCC. Prior chemotherapy treatment in the adjuvant setting (no clinically detectable disease; no metastatic disease) is allowable if the end of treatment occurred at least 6 months prior to study start)
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1
  • Disease must be measurable with at least 1 uni-dimensional measurable lesion by RECIST Version 1.1 (including skin lesions)
  • Adequate hematological, hepatic and renal function (renal function considered adequate as per protocol definition)
  • Highly effective contraception for both male and female participants, if the risk of conception exists
  • Fresh Biopsy or Archival Tumor Tissue
  • Estimated life expectancy of more than 12 weeks

Exclusion Criteria:

  • Participation in another interventional clinical trial within the past 30 days (participation in observational studies is permitted)
  • Concurrent treatment with a non permitted drug
  • Prior therapy with any antibody/drug targeting T-cell coregulatory proteins (immune checkpoints) such as antiprogrammed death 1 (PD-1), anti-PD-L1, or anticytotoxic T-lymphocyte antigen-4 (CTLA-4) antibody; for Part B, the Investigator must consult with the Medical Monitor and consider other co-regulatory targets such as 4-1BB
  • Concurrent anticancer treatment (for example, cytoreductive therapy, radiotherapy [with the exception of palliative bone-directed radiotherapy, or radiotherapy administered on non-target superficial lesions], immune therapy, or cytokine therapy except for erythropoietin). Radiotherapy administered to superficial lesions is not allowed if such lesions are considered target lesions in the efficacy evaluation or may influence the efficacy evaluation of the investigational agent
  • Major surgery for any reason, except diagnostic biopsy, within 4 weeks and/or if the participant has not fully recovered from the surgery within 4 weeks
  • Concurrent systemic therapy with steroids or other immunosuppressive agents, or use of any investigational drug within 28 days before the start of trial treatment. Short-term administration of systemic steroids (that is, for allergic reactions or the management of immune-related adverse events [irAE]) while on study is allowed. Also, participants requiring hormone replacement with corticosteroids for adrenal insufficiency are eligible if the steroids are administered only for the purpose of hormonal replacement and at doses <= 10 mg or equivalent prednisone per day. Note: Participants receiving bisphosphonate or denosumab are eligible.
  • Participants with active central nervous system (CNS) metastases are excluded. Participants with a history of treated CNS metastases (by surgery or radiation therapy) are not eligible unless they have fully recovered from treatment, demonstrated no progression for at least 2 months, and do not require continued steroid therapy
  • Previous malignant disease (other than MCC) within the last 5 years with the exception of basal or squamous cell carcinoma of the skin and for Part A cervical carcinoma in situ or for Part B carcinoma in situ (skin, bladder, cervical, colorectal, breast or low grade prostatic intraepithelial neoplasia or Grade 1 prostate cancer)
  • Prior organ transplantation, including allogeneic stem-cell transplantation
  • Part A: Known history of testing positive for HIV or known acquired immunodeficiency syndrome (AIDS) or any positive test for hepatitis B virus or hepatitis C virus indicating acute or chronic infection. For Part B, known history of testing positive for HIV or known AIDS in consultation with the Medical Monitor or HBV or HCV infection at screening (positive HBV surface antigen or HCV RNA if anti- HCV antibody screening test positive).
  • Active or history of any autoimmune disease (except for participants with vitiligo) or immunodeficiencies that required treatment with systemic immunosuppressive drugs
  • Known severe hypersensitivity reactions to monoclonal antibodies (Grade greater than or equal to (>=) 3 NCI CTCAE v 4.0), any history of anaphylaxis, or uncontrolled asthma (that is, 3 or more features of partially controlled asthma)
  • Persisting toxicity related to prior therapy Grade > 1 NCI-CTCAE v 4.0; however, sensory neuropathy Grade <= 2 is acceptable 14. Pregnancy or lactation
  • Known alcohol or drug abuse
  • Clinically significant (that is, active) cardiovascular disease: cerebral vascular accident / stroke (< 6 months prior to enrollment), myocardial infarction (< 6 months prior to enrollment), unstable angina, congestive heart failure (New York Heart Association Classification Class >= II), or serious cardiac arrhythmia requiring medication
  • All other significant diseases (for example, inflammatory bowel disease), which, in the opinion of the Investigator, might impair the participant's tolerance of trial treatment
  • Any psychiatric condition that would prohibit the understanding or rendering of informed consent
  • Legal incapacity or limited legal capacity
  • Non oncology vaccine therapies for prevention of infectious disease (for example, seasonal flu vaccine, human papilloma virus vaccine) within 4 weeks of trial drug administration. Vaccination while on trial is also prohibited except for administration of inactivated vaccines (for example, inactivated seasonal influenza vaccine)

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02155647


Locations
Hide Hide 61 study locations
Layout table for location information
United States, California
UCLA Medical Center
Los Angeles, California, United States, 90024
The Angeles Clinic and Research Institute - West LA
Los Angeles, California, United States, 90025
United States, Colorado
University of Colorado
Aurora, Colorado, United States, 80045
United States, Florida
H. Lee Moffitt Cancer Center and Research Institute, Inc
Tampa, Florida, United States, 33612
United States, Maryland
National Cancer Institute
Bethesda, Maryland, United States, 20892
United States, Massachusetts
Dana Farber Cancer Institute
Boston, Massachusetts, United States, 02215-5418
United States, Missouri
Washington University School of Medicine
Saint Louis, Missouri, United States, 63110
United States, New Jersey
Rutgers Cancer Institute of New Jersey
New Brunswick, New Jersey, United States, 08901-1914
United States, New York
Memorial Sloan Kettering Cancer Center
New York, New York, United States, 10021
Mount Sinai
New York, New York, United States, 10029
United States, Oklahoma
Peggy & Charles Stephenson Oklahoma Cancer Center
Oklahoma City, Oklahoma, United States, 73104
United States, Pennsylvania
Fox Chase Cancer Center
Philadelphia, Pennsylvania, United States, 19111
University of Pittsburgh
Pittsburgh, Pennsylvania, United States, 15213
United States, Washington
University of Washington - Seattle Cancer Care Alliance
Seattle, Washington, United States, 98109
Australia, New South Wales
Port Macquarie Base Hospital
Port Macquarie, New South Wales, Australia, 2444
Royal North Shore Hospital
St Leonards, New South Wales, Australia, 2065
Australia, Queensland
Tasman Oncology Research Ltd
Southport, Queensland, Australia
Princess Alexandra Hospital
Woolloongabba, Queensland, Australia, 4102
Australia, Victoria
Peter MacCallum Cancer Centre
East Melbourne, Victoria, Australia, 3128
Australia, Western Australia
St John of God Subiaco Hospital
Perth, Western Australia, Australia, 6000
France
CHU Nice - Hopital de l Archet 2
Nice cedex 3, Alpes Maritimes, France, 06202
Hôpital de la Timone
Marseille cedex 05, Bouches-du-Rhône, France, 13385
CHU Besançon - Hôpital Jean Minjoz
Besançon Cedex, Doubs, France, 25030
Hôpital Ambroise Paré - Boulogne-Billancourt
Boulogne Billancourt, Hauts De Seine, France, 92100
CHU Nantes - Hôtel Dieu
Nantes Cedex 1, Loire Atlantique, France, 44093
Hopital Claude Huriez - CHU Lille
Lille cedex, Nord, France, 59037
Hôpital Saint-Louis
Paris Cedex 10, Paris, France, 75475
Centre Hospitalier Lyon Sud
Pierre Benite cedex, Rhone, France, 69495
Institut Gustave Roussy
Villejuif cedex, Val De Marne, France, 94805
Groupe Hospitalier Saint André - Hôpital Saint André
Bordeaux, France
CHU Tours - Hôpital Trousseau
Chambray Les Tours, France
CHU de Dijon - Hopital du Bocage
Dijon, France
CHU de Grenoble - Hôpital A Michallon
Grenoble, France
CHU de Limoges - Hôpital Dupuytren
Limoges, France
Germany
Universitaetsklinikum Heidelberg
Heidelberg, Baden Wuerttemberg, Germany, 69120
Klinikum der Johann Wolfgang Goethe-Universitaet
Frankfurt, Hessen, Germany, 60590
St. Josef-Hospital Universitaetsklinikum
Bochum, Nordrhein Westfalen, Germany, 44791
Universitaetsklinikum Essen
Essen, Nordrhein Westfalen, Germany, 45122
Universitaetsklinikum Koeln
Koeln, Nordrhein Westfalen, Germany, 50937
Fachklinik Hornheide
Muenster, Nordrhein Westfalen, Germany, 48157
Universitaetsklinikum Carl Gustav Carus TU Dresden
Dresden, Sachsen, Germany, 01307
Universitaetsklinikum Schleswig-Holstein - Klinik fuer Allgemeine Innere Medizin
Kiel, Schleswig Holstein, Germany, 24105
Universitaetsklinikum Schleswig Holstein - Campus Luebeck
Luebeck, Schleswig Holstein, Germany, 23538
Helios Klinikum Erfurt
Erfurt, Thueringen, Germany, 99089
Charite Universitaetsmedizin Berlin - Campus Charite Mitte
Berlin, Germany, 10117
Italy
Fondazione del Piemonte per l'Oncologia IRCC Candiolo
Candiolo, Torino, Italy, 10060
Fondazione IRCCS Istituto Nazionale dei Tumori
Milano, Italy, 20133
IEO Istituto Europeo di Oncologia
Milano, Italy, 20141
Istituto Nazionale Tumori Fondazione G.Pascale
Napoli, Italy, 80131
IOV - Istituto Oncologico Veneto IRCCS
Padova, Italy, 35128
Azienda Ospedaliera di Perugia Ospedale S. Maria della Misericordia
Perugia, Italy, 06156
Arcispedale S. Maria Nuova Azienda Ospedaliera di Reggio Emilia
Reggio Emilia, Italy, 42100
Istituto Nazionale Tumori Regina Elena IRCCS
Roma, Italy, 00144
A.O.U. Senese Policlinico Santa Maria alle Scotte
Siena, Italy, 53100
Japan
Shizuoka Cancer Center
Shizuoka, Shizuoka-Ken, Japan, 411-8777
National Cancer Center Hospital
Chuo-ku, Tokyo-To, Japan, 104-0045
Spain
Hospital Universitari Vall d'Hebron
Barcelona, Spain, 08035
Hospital Clinic i Provincial de Barcelona
Barcelona, Spain, 08036
Hospital General Universitario Gregorio Marañon
Madrid, Spain, 28007
Hospital Universitario 12 de Octubre
Madrid, Spain, 28041
Hospital General Universitario de Valencia
Valencia, Spain, 46014
Sponsors and Collaborators
EMD Serono Research & Development Institute, Inc.
Investigators
Layout table for investigator information
Study Director: Medical Responsible Merck KGaA, Darmstadt, Germany
  Study Documents (Full-Text)

Documents provided by EMD Serono ( EMD Serono Research & Development Institute, Inc. ):
Statistical Analysis Plan  [PDF] March 31, 2016
Study Protocol  [PDF] May 25, 2018

Additional Information:
Publications of Results:
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Layout table for additonal information
Responsible Party: EMD Serono Research & Development Institute, Inc.
ClinicalTrials.gov Identifier: NCT02155647    
Other Study ID Numbers: 100070-003
2014-000445-79 ( EudraCT Number )
First Posted: June 4, 2014    Key Record Dates
Results First Posted: July 22, 2020
Last Update Posted: January 5, 2021
Last Verified: December 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description: Per company policy, following approval of a new product or a new indication for an approved product in both the EU and the US, EMD Serono will share study protocols, anonymized patient level and study level data and redacted clinical study reports from clinical trials in patients with qualified scientific and medical researchers, upon request, as necessary for conducting legitimate research. Further information on how to request data can be found on our website https://www.emdgroup.com/en/research/our-approach-to-research-and-development/healthcare/clinical-trials/commitment-responsible-data-sharing.html
Supporting Materials: Analytic Code
Keywords provided by EMD Serono ( EMD Serono Research & Development Institute, Inc. ):
Carcinoma, Merkel Cell
MSB0010718C
avelumab
Bavencio
anti PD-L1
JAVELIN Merkel 200
Additional relevant MeSH terms:
Layout table for MeSH terms
Carcinoma, Merkel Cell
Carcinoma
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Neoplasms
Polyomavirus Infections
DNA Virus Infections
Virus Diseases
Tumor Virus Infections
Carcinoma, Neuroendocrine
Neuroendocrine Tumors
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Adenocarcinoma
Neoplasms, Nerve Tissue